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Abstract
Long-term survivors of childhood cancers are at increased risk for hospitalization. To test the 
hypothesis that many treatment-related morbidities are identifiable in the early post-therapy 
period, we determined the rates and causes for hospitalization among survivors of leukemia and 
lymphoma during the first three years post-therapy. Using a health plan claims database, we 
identified patients aged 0-21 years-old treated for leukemia or lymphoma from 2000-2010. 
Survivors were matched 10:1 with similar children without a history of cancer. Hospitalization 
rates over three years were compared using Cox proportional hazards regression and risks of 
cause-specific hospitalization were compared using log-binomial models. Nineteen percent of 
childhood leukemia and lymphoma survivors were hospitalized in the first three years off therapy. 
Leukemia survivors (N=529) experienced over six times (HR: 6.3, 95%CI: 4.9-8.0) and lymphoma 
survivors (N=454) over three times the hospitalization rate of controls (HR: 3.2, 95%CI: 2.5-4.2). 
Compared with children without a cancer history, survivors were at increased risk for 
hospitalization due to infectious causes (leukemia RR: 60.0, 95%CI: 23.4-154.0; lymphoma RR: 
10.0, 95%CI: 4.4-22.9). Additionally, lymphoma survivors were at increased risk for 
cardiovascular-(RR: 15.0, 95%CI: 5.4-42.0) and pulmonary-(RR: 8.1, 95%CI: 3.9-16.8) related 
hospitalizations. These findings highlight the morbidity experienced by survivors and suggest that 
treatment-associated complications may be emerging soon after therapy completion.
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 Introduction
With increased survival for childhood cancers, there is a growing population of childhood 
cancer survivors estimated to be nearly 380,000 individuals in the United States in 2010.1 
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While the incidence of childhood cancers is relatively low compared to that in adults, more 
than 80% of childhood cancer patients will become long-term survivors.2 Approximately 
two-thirds of survivors will have at least one major medical problem related to their prior 
therapy, and one-third will experience a complication that is severe or life-threatening.3 In 
2005 the Institute of Medicine recommended lifelong risk-based medical care for all 
survivors of cancer as many medical conditions in this population can be avoided or limited 
by screening and early detection.4
Studies have suggested that survivors are not receiving the risk-based follow-up care 
necessary to identify and prevent cancer-related comorbidities.5-7 Comorbidities associated 
with prior treatment may lead to increased rates of high-acuity health care encounters such 
as hospitalizations. Prior studies have found an increased risk for hospitalization and longer 
lengths of stay among long-term survivors of childhood cancer.8-12 The patterns of 
hospitalizations among childhood cancer survivors in the immediate period following 
completion of therapy have not been reported. Hospitalizations provide an indicator for the 
level of medical morbidities experienced by a population. A better understanding of early 
hospitalizations may allow for the identification of treatment-related morbidities that already 
are developing soon after completion of therapy.
The purpose of this study was to determine the hospitalization rates for childhood leukemia 
and lymphoma survivors in the first three years post-therapy as compared with a cohort of 
matched children without a history of cancer. We hypothesize that, despite having completed 
active cancer treatment, survivors continue to require more high-acuity medical care than 
children without a history of cancer due to morbidities arising in the early post-therapy 
period. Secondarily, we sought to describe the causes for hospitalizations in order to 
improve our understanding of the particular types of morbidities developing during this time 
period.
 Materials and Methods
 Patient Cohort
Using the Truven Health Marketscan® Commercial Claims and Encounters database,13 we 
identified pediatric and young adult patients (21 years-old and younger) treated for leukemia 
or lymphoma from January 1, 2000 to December 31, 2010. This data source includes de-
identified inpatient, outpatient and pharmacy insurance claims data for over 50 million 
individuals and their dependents who are insured by commercial health plans in the United 
States. We identified children with leukemia (acute lymphoblastic and acute myeloid 
leukemias) and lymphoma (Hodgkin and non-Hodgkin lymphomas) using the AHRQ 
Clinical Classifications Software (CCS)14 matched to International Classification of 
Diseases, ninth revision (ICD-9) codes for leukemia and lymphoma (CCS codes 37-38 for 
lymphomas and 39 for leukemia). Due to small sample sizes, patients were not stratified 
beyond the groupings of leukemia and lymphoma. We further restricted our cohort to those 
patients with Healthcare Common Procedure Coding System (HCPCS) codes or Current 
Procedural Terminology (CPT) codes and outpatient prescription drug claims for appropriate 
chemotherapy or radiation therapy (Supplemental Table). End of treatment (EOT) was 
defined at the last observed chemotherapy or radiation therapy date. This included the date 
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of last inpatient or outpatient claim use of chemotherapy or radiation therapy or the last fill 
date for oral chemotherapy. Patients were required to have three years of continuous health 
plan enrollment from the EOT in order to capture post-therapy hospitalizations. Patients who 
relapsed during the study period and underwent subsequent therapy were not included due to 
our defining the end of therapy based on the cessation of billing codes for treatment. Persons 
having ICD-9 codes for both leukemia and lymphoma were excluded. Individuals with 
procedural billing codes associated with hematopoietic stem cell transplant were excluded 
from the analysis population. After all exclusions there were 983 children included in our 
cancer cohort.
We selected a comparison cohort of children in the database without claims for a cancer 
diagnosis matched for three year continuous enrollment profile, age, sex and geographic 
region. Separate comparison cohorts were created for the leukemia and lymphoma cohorts. 
Controls were randomly sampled 10:1 from the MarketScan database.
The study design was reviewed by the UNC IRB and determined to qualify for a waiver as 
Not Human Subjects Research (NHSR).
 Measures—The primary study outcome was hospitalization. Hospitalizations per person 
and time to first hospitalization were determined during the three years post-therapy. 
Hospitalization incidence rates were determined for the total three year period (reported as 
events per 100 patient-years) as well as for 6 month increments in order to determine trends 
following the end of treatment. Because hospitalization rates may be affected by recently 
completed therapy or by continued use of oral medications beyond the assigned EOT, we 
excluded hospitalizations occurring in the first month following the EOT. Length of stay per 
hospitalization was also determined for each admission. The diagnoses associated with each 
hospitalization were classified using the major diagnostic criteria (MDC) from the 
MarketScan inpatient database. This standardized method of admission categorization is 
based on both primary diagnosis classification and procedure coding.
 Statistical Analysis—Demographic variables were compared between cancer and 
control cohorts using chi-square and student t-tests as appropriate. The median number of 
hospitalizations per person and length of stay were calculated. Cox proportional hazards 
models were used to estimate the risk for hospitalization over the three years post-therapy 
for survivors and matched controls. Log-binomial models were used to assess the risk for 
cause-specific hospitalization between survivors and matched cohorts. Statistical analyses 
were performed using SAS® Version 9.4 software (SAS Institute, Inc., Cary, NC).
 Sensitivity Analyses—A sensitivity analysis sampling at a 25:1 ratio was performed to 
confirm observed hospitalization rates among the controls. Observed rates were comparable 
for both sampling populations and were consistent with previously published rates for 
children and adolescents.15 For this reason, we proceeded with 10:1 sampling.
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 Results
Five hundred and twenty-nine survivors of leukemia and 454 survivors of lymphoma were 
identified. As expected, patients with lymphoma were older than those with leukemia (mean 
age 15.6 years and 8.7 years, respectively). Fifty-five percent of leukemia survivors and 59% 
of lymphoma survivors were male. More patients were from the South than from any other 
region of the US due to health plan participation with the MarketScan database. Most 
patients were enrolled in a preferred provider organization (PPO) health plan. The number of 
patients reaching the EOT per year increased by over 10-fold during the study period which 
is a reflection of the growing number of enrollees within health plans included in 
MarketScan between 2000 and 2010. Controls were well-matched to the study cohorts 
(Table 1).
Approximately 20% of leukemia survivors and 18% of lymphoma survivors were 
hospitalized during the first three years post-therapy. Among leukemia survivors, the 
incidence rate of hospitalizations was 16.7 versus 1.7 per 100 patient-years for controls. 
Among lymphoma survivors, the rate of hospitalizations was 11.1 versus 2.7 per 100 
patient-years for controls. More hospitalizations (34% among leukemia survivors and 28% 
among lymphoma survivors) occurred within the first six months following therapy 
completion than in any other time period. However, a sustained increased rate over the three 
years of observation was noted among both survivors of leukemia and lymphoma when 
compared to matched controls (Figure 1).
In adjusted hazard models, survivors of leukemia experienced over six times the rate of 
hospitalization of controls (HR: 6.3, 95%CI: 4.9-8.0, P<0.0001) and survivors of lymphoma 
over three times the rate of controls (HR: 3.2, 95%CI: 2.5-4.2, P<0.0001). Survivors and 
controls who were ever hospitalized tended to be hospitalized once over the three years with 
median lengths of stay of 3 days for survivors and 2 days for controls (Table 2).
Leukemia and lymphoma survivors also demonstrated increased risk for cause-specific 
hospitalizations compared to controls (Figure 2). Leukemia survivors were at increased risk 
of hospitalization for many conditions including infectious (RR: 60.0, 95%CI: 23.4-154.0), 
blood (RR: 36.0, 95%CI: 13.4-96.6), endocrine (RR: 14.3, 95%CI: 5.5-37.4) and pulmonary 
(RR: 8.9, 95%CI: 5.2-15.3) disorders. Lymphoma survivors were at increased risk for 
infections (RR: 10.0, 95%CI: 4.4-22.9), cardiovascular disorders (RR: 15.0, 95%CI: 
5.4-42.0) and disorders of the pulmonary system (RR: 8.1, 95%CI: 3.9-16.8). Neither 
leukemia nor lymphoma survivors were at increased risk for hospitalization due to substance 
abuse or psychiatric-related conditions.
 Discussion
Our findings demonstrate that survivors of childhood leukemia and lymphoma are at a 
markedly increased risk for hospitalization in the first three years following the completion 
of therapy with nearly one-fifth of all survivors having at least one hospitalization during 
this period. We observed that survivors of leukemia experience over six times, and survivors 
of lymphoma over three times, the hospitalization rate of controls. Once active therapy for 
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these patients is complete, survivors continue to face a significant health care burden 
necessitating ongoing high-acuity encounters during the early post-therapy period. Long-
term sequelae of cancer treatment (20 to 30 years after treatment) have been well described. 
Our results suggest that medical complications may arise soon after therapy is completed for 
some survivors.
Many of the hospitalizations among survivors occurred in the first six months off therapy. 
Increased hospitalization rates during this time are not surprising as survivors are recovering 
from the acute effects of treatment. Such hospitalizations may not be indicative of 
developing long-term morbidities, but rather, of temporary therapy-related complications. 
However, while the hospitalization rates were highest among survivors in the first six 
months following therapy completion, the increased rate compared to controls persisted 
throughout the three-year study period. As patients are recovering from the 
immunosuppressive and myelosuppressive effects of active therapy, they are clearly at the 
highest risk for hospitalization in the early post-therapy, but the increased risk remains 
among survivors.
Our results add to prior studies reporting increased rates of hospitalization among long-term 
survivors of pediatric cancers. Generally these studies have reported outcomes among 
survivors more than 10 years off therapy. Increased risks of 1.5 to nearly 5 times that of 
controls have been reported for all pediatric cancer survivors as well as for specific leukemia 
and lymphoma subgroups.8-12 Additionally, survivors of young adult cancers (diagnosis 
20-44 years-old) have been observed to have higher hospitalization rates than controls.16 
Comparable to our findings, this study also found that hospitalization rates for survivors 
decreased with time from diagnosis but remained higher than that among controls for all 
time periods. Our findings are distinct from these prior studies given our focus on the early 
post-therapy period. Further, we utilized data from a large population-based insured cohort 
allowing for deeper understanding of services used among privately-insured children. Our 
goal was to extend what is known regarding the increased risk for hospitalization among 
long-term survivors to those who have recently completed active therapy and to describe 
patterns that might lead to identification of developing post-therapy morbidities.
In addition to an increased overall risk for hospitalization, childhood cancer survivors also 
experience an increased risk for cause-specific hospitalization due to a wide range of 
diagnoses. Consistent with prior studies, we found that survivors of both cancer types were 
at increased risk for hospitalizations due to infectious causes.10,11 Such a high burden of 
infectious complications is not surprising given the immunosuppression associated with 
treatment for leukemia and lymphoma and underscores the importance of limiting potential 
sources of infection as expeditiously as possible once therapy is complete. One such 
intervention may be to remove central venous catheters as quickly as possible when 
transitioning off therapy.
Survivors of leukemia were also at increased risk for hospitalizations due to hematologic 
disorders. After prolonged therapy, recovery of bone marrow function may take time leading 
to a susceptibility to cytopenias necessitating hospitalization. One could argue that the 
hospitalizations associated with infectious and hematologic causes are issues expected to 
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resolve with reconstitution of a patient’s immune system and bone marrow function 
following completion of therapy. This is consistent with the decline in hospitalizations we 
noted after the first six months off therapy. However, long-term survivors continue to have a 
significantly increased risk for hospitalization well beyond three years post-therapy, and 
infectious and hematologic complications are common causes for hospitalizations even 
decades following therapy completion.10,11This suggests that these issues do not fully 
resolve with time off therapy and remain a significant contributor to ongoing survivor 
morbidity.
In addition to infections, we found high rates of cardiovascular, pulmonary, and endocrine 
complications among cancer survivors. Specifically, lymphoma survivors had significantly 
increased risk for hospitalizations due to cardiovascular and pulmonary causes – organ 
systems known to be at risk for ongoing treatment-related toxicities following therapy 
completion. These morbidities have been primarily reported among long-term survivors17-22 
and are associated with increased long-term hospitalization rates.10 Our findings suggest that 
these complications may be developing earlier than previously anticipated among some 
survivors.
In our analysis, we observed a high rate of hospitalizations for mental health disorders 
among lymphoma survivors. An increased risk for mental health hospitalization has been 
previously reported among Danish survivors of childhood cancers.23 However, when 
compared to the control group, the hospitalization rates for psychiatric causes we observed 
were no higher than those of the general pediatric population. Our findings are consistent 
with other studies that reported no increased risk of psychiatric hospitalization among 
pediatric cancer survivors12 and that found an increased risk only among the subset of 
survivors of brain tumors.24
These findings should be interpreted in the context of several limitations. While our study 
examined hospitalizations among a nationally distributed cohort of survivors, only survivors 
continuously enrolled in private health care insurance plans were included. Our findings may 
not represent survivors with public health care insurance coverage or no coverage. A prior 
study reported that insured survivors and those with household incomes under $20,000 are at 
increased risk for hospitalization.10 This suggests that those with public health care coverage 
may be at increased risk for hospitalization as compared to survivors covered by private 
health care plans. Consequently, our estimates among privately insured individuals may 
actually underestimate the true risk among all survivors. Additionally, we only considered 
survivors of childhood leukemia or lymphoma. We limited our study population for several 
reasons. Primarily these diagnoses are two of the most prevalent among pediatric patients, 
yielding suitably large study populations. Additionally, the multimodal treatment for these 
conditions provides ample opportunity to utilize procedural and treatment codes to confirm 
the diagnoses and to determine the end of treatment. Examination of hospitalization patterns 
in the early post-therapy period for survivors of all cancers is a potential future direction. 
Small sample sizes for certain cancer subtypes precluded further stratification of patients 
beyond the groupings of leukemia or lymphoma.
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Next, we defined end of treatment based on the last observed claim for infused or oral 
chemotherapy or radiotherapy. Some patients may continue to use oral therapies following 
the assigned EOT date which may lead to misclassification. In order to limit the inclusion of 
hospitalizations while patients were undergoing active therapy, we excluded hospitalizations 
during the first month following the identified end of treatment date.
The secondary analysis of administrative claims data also presents certain limitations. 
Patient classification and outcomes of interest are dependent on appropriate coding. We have 
attempted to minimize misclassification by requiring patients to meet multiple criteria for 
inclusion as survivors – requiring evidence of both diagnoses and procedures for leukemia 
and lymphoma and their treatment. Due to limitations of the data we are unable to 
distinguish between primary and secondary cancers, so individuals with relapsed or 
secondary cancers who completed therapy during our assessment period would be classified 
similarly to those completing treatment for their initial diagnosis. Although hospitalizations 
are likely to be accurately identified, reasons for hospitalizations may be less consistently 
captured. The major diagnosis categories (MDC) provide objective and reproducible 
indicators for the reasons underlying hospitalizations, but they only offer a general 
understanding for the cause of the hospitalization at an organ system level and may lack 
some specificity. For instance, a condition such as pneumonia may be classified as a 
pulmonary instead of an infectious diagnosis. While this is correct, one may argue that a 
condition such as pneumonia is primarily secondary to an infectious cause and not a disorder 
of the lung itself. Finally hospitalizations provide an incomplete picture of medical 
complications as survivors may develop medical morbidities not severe enough to warrant 
inpatient hospitalization. Future studies should investigate treatment for less severe 
morbidites through investigation of patterns of outpatient and prescription drug use.
In conclusion, our findings suggest that pediatric leukemia and lymphoma survivors are at 
high risk for hospitalization following therapy completion, with the highest risk occurring 
immediately after the end of treatment but persisting over the first three years post-therapy. 
Often the focus for patient follow-up encounters during this time is surveillance for disease 
recurrence. Our findings suggest that attention should also be given to the detection and 
prevention of treatment-associated morbidities during the early off-therapy period. This 
could include implementing infection control measures, such as early central catheter 
removal, and more targeted surveillance with careful attention to obtaining the 
recommended risk-based screening for treatment-related morbidities even in the early post-
therapy period.
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Figure 1. 
Hospitalization incidence rate per 100 subjects over time from the end of treatment.
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Figure 2. 
Relative risks and 95% confidence intervals for cause-specific hospitalizations among all 
survivors of leukemia (2a) and lymphoma (2b) compared to controls. Psychiatric: includes 
substance abuse and psychiatric-related admissions.
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Table 1
Baseline Characteristics of Cancer Survivors and Matched Controls
Leukemia
(N = 529)
Controls
(N = 5,290)
Lymphoma
(N = 454)
Controls
(N = 4,540)
Age [Mean (SD)] 8.7 (4.75) 8.7 (4.75) 15.6 (4.24) 15.6 (4.24)
Sex [N (%)]
Female 239 (45) 2390 (45) 186 (41) 1860 (41)
Male 290 (55) 2900 (55) 268 (59) 2680 (59)
Region [N (%)]a
Northeast 80 (15) 662 (13) 59 (13) 517 (11)
North Central 142 (27) 1439 (27) 116 (26) 1172 (26)
South 191 (37) 2140 (41) 183 (40) 1180 (42)
West 109 (21) 1013 (19) 93 (21) 946 (21)
Plan Type [N (%)]a
Health Maintenance Organization 111 (21) 949 (18) 79 (18) 764 (17)
Preferred Provider Organization 317 (61) 3198 (62) 261 (58) 2772 (63)
Other 95 (18) 1026 (20) 108 (24) 886 (20)
Year of EOT [N (%)]
2000 8 (2) 80 (2) 6 (1) 60 (1)
2001 10 (2) 100 (2) 6 (1) 60 (1)
2002 17 (3) 170 (3) 17 (4) 170 (4)
2003 33 (6) 330 (6) 29 (6) 290 (6)
2004 30 (6) 300 (6) 40 (9) 400 (9)
2005 33 (6) 330 (6) 31 (7) 310 (7)
2006 55 (10) 550 (10) 44 (10) 440 (10)
2007 69 (13) 690 (13) 52 (11) 520 (11)
2008 77 (15) 770 (15) 72 (16) 720 (16)
2009 84 (16) 840 (16) 72 (16) 720 (16)
2010 113 (21) 1130 (21) 85 (19) 850 (19)
aUnknown or missing data were excluded; SD: Standard Deviation; EOT: End of Treatment
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Table 2
Comparisons of hospitalization rates, hospitalizations per child, and lengths of stay between cancer cohorts 
and controls.
Hospitalizations
Hospitalizations per
Childc Length of Stay
c
Ratea HRb 95% CI
p-
value
Mean
(SD)
Median
(IQR)
Mean
(SD)
Median
(IQR)
Leukemia
Controls
16.7 6.3 4.9-8.0 <.0001 2.5 (2.9) 1 (1-3) 5.5 (9.4) 3 (2-5)
1.7 1 Referent 1.4 (1.0) 1 (1-1) 4.0 (5.2) 2 (1-4)
Lymphoma
Controls
11.1 3.2 2.5-4.2 <.0001 1.9 (2.0) 1 (1-2) 6.1 (7.9) 3 (2-6)
2.7 1 Referent 1.4 (0.9) 1 (1-1) 3.7 (4.6) 2 (1-4)
CI: confidence interval; SD: standard deviation; IQR: interquartile range
a
Incidence rate for number of hospitalizations per 100 patient-years;
b
Hazard ratio adjusted for age, sex, geographic region and year of treatment end using Cox proportional hazards model;
cAmong patients with ≥ 1 hospitalization;
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